Very small differences in the way a patient lies during radiotherapy treatment for lung or esophageal cancer can have an impact on how likely they are to survive, according to research presented at the ESTRO 37 conference.
An analysis of elderly patients treated in a phase II trial of radiotherapy combined with chemotherapy in non-small cell lung cancer has shown that they were less likely to benefit than younger patients if the two treatments were given at the same time. The study is presented at ESTRO37 -- Europe's largest radiation oncology conference.
A simple test of handgrip strength is a good indicator of short- and long-term survival in patients with early, stage I non-small cell lung cancer (NSCLC), according to new findings to be presented at ESTRO 37 -- Europe's largest radiation oncology conference.
People with obesity are more likely to develop a rapid and irregular heart rate, called atrial fibrillation, which can lead to stroke, heart failure and other complications, according to Penn State researchers. They found that people with obesity had a 40 percent higher chance of developing atrial fibrillation than people without obesity.
A blood test to measure the levels of two proteins in plasma that are common predictors of lung cancer was 98 percent effective in a multicenter clinical trial at distinguishing benign from malignant lung nodules when combined with a patient's clinical characteristics to form an integrated classifier. These results were reported by a team of investigators at the Medical University of South Carolina in an article in Chest.
CU presentation at AACR2018 describes the first research-focused group of patients organized around the genetic mutation that creates their cancer, namely changes to the gene ROS1.
University of Colorado Cancer Center study compares outcomes of 5,752 small-cell lung cancer patients who received whole-brain radiation therapy (WBRT) with those of 200 patients who received stereotactic radiosurgery (SRS), finding that the median overall survival was actually longer with SRS (10.8 months with SRS versus 7.1 months with WBRT).
The immunotherapy drug pembrolizumab, combined with chemotherapy, doubles survival in patients with non-squamous non-small cell lung cancer (NSNSCLC) lacking genetic changes in the EGFR or ALK genes, when compared to chemotherapy alone, according to an international, Phase III clinical trial.
New research published in The Journal of Physiology has indicated why people with paralysis of their limbs and torso are more likely to suffer from sleep apnea. This knowledge could be used to develop much-need targeted therapies.
New study, 'Short-Term Elevation of Fine Particulate Matter Air Pollution and Acute Lower Respiratory Infection,' is the largest to date on this health concern, involving more than 100,000 patients.